Literature DB >> 27705251

Progress in Myeloma - A Monoclonal Breakthrough.

S Vincent Rajkumar1, Robert A Kyle1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27705251     DOI: 10.1056/NEJMe1609835

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  12 in total

1.  Multiple myeloma: 2018 update on diagnosis, risk‐stratification, and management

Authors: 
Journal:  Am J Hematol       Date:  2018-08-16       Impact factor: 10.047

Review 2.  Next-generation multiple myeloma treatment: a pharmacoeconomic perspective.

Authors:  S Vincent Rajkumar; Jean Luc Harousseau
Journal:  Blood       Date:  2016-10-14       Impact factor: 22.113

3.  Multiple myeloma in 2016: Fresh perspectives on treatment and moments of clarity.

Authors:  Prashant Kapoor; S Vincent Rajkumar
Journal:  Nat Rev Clin Oncol       Date:  2017-01-10       Impact factor: 66.675

Review 4.  Multiple myeloma: Every year a new standard?

Authors:  S Vincent Rajkumar
Journal:  Hematol Oncol       Date:  2019-06       Impact factor: 5.271

5.  Multiple myeloma: 2022 update on diagnosis, risk stratification, and management.

Authors:  S Vincent Rajkumar
Journal:  Am J Hematol       Date:  2022-05-23       Impact factor: 13.265

Review 6.  Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies.

Authors:  Gita Thanarajasingam; Lori M Minasian; Frederic Baron; Franco Cavalli; R Angelo De Claro; Amylou C Dueck; Tarec C El-Galaly; Neil Everest; Jan Geissler; Christian Gisselbrecht; John Gribben; Mary Horowitz; S Percy Ivy; Caron A Jacobson; Armand Keating; Paul G Kluetz; Aviva Krauss; Yok Lam Kwong; Richard F Little; Francois-Xavier Mahon; Matthew J Matasar; María-Victoria Mateos; Kristen McCullough; Robert S Miller; Mohamad Mohty; Philippe Moreau; Lindsay M Morton; Sumimasa Nagai; Simon Rule; Jeff Sloan; Pieter Sonneveld; Carrie A Thompson; Kyriaki Tzogani; Flora E van Leeuwen; Galina Velikova; Diego Villa; John R Wingard; Sophie Wintrich; John F Seymour; Thomas M Habermann
Journal:  Lancet Haematol       Date:  2018-06-18       Impact factor: 18.959

7.  A CS1-NKG2D Bispecific Antibody Collectively Activates Cytolytic Immune Cells against Multiple Myeloma.

Authors:  Wing Keung Chan; Siwen Kang; Youssef Youssef; Erin N Glankler; Emma R Barrett; Alex M Carter; Elshafa H Ahmed; Aman Prasad; Luxi Chen; Jianying Zhang; Don M Benson; Michael A Caligiuri; Jianhua Yu
Journal:  Cancer Immunol Res       Date:  2018-05-16       Impact factor: 11.151

Review 8.  Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed/refractory multiple myeloma.

Authors:  Tiantian Zhang; Sen Wang; Tengfei Lin; Jingmei Xie; Lina Zhao; Zhuoru Liang; Yangqiu Li; Jie Jiang
Journal:  Oncotarget       Date:  2017-05-16

Review 9.  New developments in the treatment of multiple myeloma - clinical utility of daratumumab.

Authors:  Cian McEllistrim; Janusz Krawczyk; Michael E O'Dwyer
Journal:  Biologics       Date:  2017-04-11

Review 10.  Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond.

Authors:  C S Chim; S K Kumar; R Z Orlowski; G Cook; P G Richardson; M A Gertz; S Giralt; M V Mateos; X Leleu; K C Anderson
Journal:  Leukemia       Date:  2017-11-16       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.